Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-02
2011-11-08
Weddington, Kevin E (Department: 1629)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S562000, C514S596000, C514S601000, C514S632000, C514S824000
Reexamination Certificate
active
08053449
ABSTRACT:
Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.
REFERENCES:
patent: 5334617 (1994-08-01), Ulrich et al.
patent: 5891341 (1999-04-01), Li et al.
patent: 5985857 (1999-11-01), Hudson et al.
patent: 6337350 (2002-01-01), Rahbar et al.
patent: 6410598 (2002-06-01), Vitek et al.
patent: 6589944 (2003-07-01), Rahbar
patent: 6605642 (2003-08-01), Rahbar et al.
patent: 6613801 (2003-09-01), Mjalli et al.
patent: 6787566 (2004-09-01), Rahbar
patent: 6908741 (2005-06-01), Shahbaz
patent: 7030133 (2006-04-01), Rahbar et al.
patent: 7067554 (2006-06-01), Mjalli et al.
patent: 7087632 (2006-08-01), Mjalli et al.
patent: 2004/0137068 (2004-07-01), Bhushan
patent: 2005/0171150 (2005-08-01), Rahbar et al.
patent: 2006/0148760 (2006-07-01), Mjalli et al.
patent: 2006/0189578 (2006-08-01), Mjalli et al.
patent: 2007/0032430 (2007-02-01), Fogelman et al.
patent: 02/076443 (2002-10-01), None
Miyata et al., “Mechanism of the Inhibitory Effect of OPB-9195[(±)-2-lsopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanilide] on Advanced Glycation End Products and Advanced Lipoxidation End Product Formation”, Journal of American Society of Nephrology, vol. 11, No. 9, pp. 1719-1725 (2000).
Schmidt AM “Glycation, RAGE and the complications of diabetes.” No date available.
Boel, E., “Diabetic Late Complications: Will Aldose Reductase Inhibitors or Inhibitors of Advanced Glycosylation Endproduct Formation Hold Promise?”, Journal of Diabetes and Its Complications, vol. 9, 1995, pp. 104-129.
Bucala, R., “Advanced Glycosylation: Chemistry, Biology, and Implications for Diabetes and Aging”, Advances in Pharmacology, vol. 23, 1992, pp. 1-16.
Bucala, R., “Lipid advanced glycosylation: Pathway for lipid oxidation in vivo”, Proc. Natl. Acad. Sci., vol. 90, Jul. 1993, pp. 6434-6438.
Kalousava, M., “Advanced Glycation End Products in Clinical Nephrology”, Kidney Blood Press Res, vol. 27, 2004, pp. 18-28.
Miyata, T., “Mechanism of the Inhibitory Effect of OPB-9195 [(±)-2-Isopropylidenehydrazono-4-oxo-thiazolidin-5-ylacetanllide] on Advanced Glycation End Product and Advanced Lipoxidation End Product Formation”, J.Am Soc Nephrol., vol. 11, 2000, pp. 1719-1725.
Rahbar, S., “Hemoglobin H Disease in Two Iranian Families”, Clin. Chim. Acta, vol. 20, 1968, pp. 381-385.
Rahbar, S., “Studies of an Unusual Hemoglobin in Patients with Diadetes Mellitus”, Biochemical and Biophysical Reseach Communications, vol. 36, No. 5, 1969, pp. 838-843.
Rahbar, S., “Novel Inhibitors of Advanced Glycation Endproducts”, Biochemical & Biophysical Research Communications, vol. 262, 1999, pp. 651-656.
Rahbar, S., “Inhibitors and Breakers of Advanced Glycation Endproducts (AGEs): A Review”, Curr. Med. Chem. Immun. Endoc. & Metab. Agents, vol. 2, 2002, pp. 135-161.
Wendt T., “Glucose, Glycation, and RAGE: Implications for Amplification of Cellular Dysfunction in Diabetic Nephropathy”, J. Am Soc Nephrol. vol. 14, 2003, pp. 1383-1395.
Maillard LC. “Synthesis of humic Materials by the action of amino acids and reducing sugars.” Ann. Chim. 5:258-317, 1916.
Cell Viable Corporation
Costigan James V.
Hedman & Costigan ,P.C.
Weddington Kevin E
LandOfFree
Method for inhibiting AGE complex formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting AGE complex formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting AGE complex formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4277550